{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:10:03Z","timestamp":1756300203383,"version":"3.44.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Das Basalzellkarzinom (BCC) ist bei Patienten \u2264\u202f50\u00a0Jahre selten und kann mit Tumorpr\u00e4dispositionssyndromen (TPDS) assoziiert sein. Das BAP1-TPDS hat f\u00fcr Augen\u00e4rzte eine besondere Relevanz, da es mit Aderhautmelanomen und anderen malignen nichtokul\u00e4ren Tumoren assoziiert ist.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ziel der Arbeit<\/jats:title>\n            <jats:p>Retrospektive Analyse von Patienten \u2264\u202f50\u00a0Jahre mit periokul\u00e4ren BCCs im Hinblick auf demografische, klinische und histologische Merkmale zur Identifikation von TPDS inklusive der BAP1-F\u00e4rbung als m\u00f6gliches Screeningverfahren f\u00fcr das BAP1-TPDS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material und Methoden<\/jats:title>\n            <jats:p>Identifikation aller im Zeitraum 1996 bis 2024 an unserer Klinik operierten Patienten \u2264\u202f50\u00a0Jahre mit histologisch gesichertem BCC. Erhebung von Lokalisation und histologischem Subtyp sowie Auswertung der immunhistochemischen BAP1-F\u00e4rbung.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse<\/jats:title>\n            <jats:p>Im Beobachtungszeitraum wurden 38\u00a0Patienten \u2264\u202f50\u00a0Jahre mit einem BCC der okul\u00e4ren Adnexe identifiziert, davon 5\u00a0Patienten mit multiplen BCCs. Das Durchschnittsalter bei Exzision betrug 42,7\u00a0Jahre. Das histologische Wachstumsmuster war \u00fcberwiegend nodul\u00e4r (89\u202f%), und die Lokalisation der Tumoren waren in absteigender Reihenfolge Unterlid (53\u202f%), medialer Lidwinkel (26\u202f%) und Oberlid (21\u202f%). Zwei Patienten wiesen ein TPDS auf (Gorlin-Goltz-Syndrom und Xeroderma pigmentosum). Die Mehrheit der untersuchten Tumoren zeigten eine deutliche BAP1-F\u00e4rbereaktion (89\u202f%). Ein Anteil positiver Tumorzellen unter 25\u202f% lag nur bei insgesamt 4\u00a0Pr\u00e4paraten vor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diskussion<\/jats:title>\n            <jats:p>Bei Patienten mit BCC \u2264\u202f50\u00a0Jahre oder mit multiplen anderen Tumorentit\u00e4ten sollte an ein TPDS gedacht werden. Die BAP-1-Immunf\u00e4rbung ist \u2013\u00a0wenngleich in unserer Studie nicht wegweisend\u00a0\u2013 dahingehend besonders interessant, da sie ein kosteng\u00fcnstiges Screening auf ein BAP1-TPDS darstellen k\u00f6nnte und ohne deutlich erh\u00f6hten Arbeitsaufwand m\u00f6glich ist.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00347-025-02273-z","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:13:38Z","timestamp":1754482418000},"page":"708-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Charakterisierung periokul\u00e4rer Basalzellkarzinome von Patienten \u2264\u202f50\u00a0Jahre von\u00a01996\u00a0bis\u00a02024","Characterization of periocular basal cell carcinoma in patients \u2264\u202f50\u00a0years from 1996\u20132024"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1515-1863","authenticated-orcid":false,"given":"Jonathan","family":"Meinke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin U.","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick N.","family":"Liermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina C.","family":"Herwig-Carl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2273_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100227","author":"Z Ba\u015f","year":"2023","unstructured":"Ba\u015f\u00a0Z, Sharpe\u00a0J, Yaghy\u00a0A, Zhang\u00a0Q, Shields\u00a0CL, Hyman\u00a0L (2023) Prevalence of and Associated Factors for Eyelid Cancer in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmol Sci. https:\/\/doi.org\/10.1016\/j.xops.2022.100227","journal-title":"Ophthalmol Sci"},{"issue":"9","key":"2273_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/ddg.12798","volume":"13","author":"M Alter","year":"2015","unstructured":"Alter\u00a0M, Hillen\u00a0U, Leiter\u00a0U, Sachse\u00a0M, Gutzmer\u00a0R (2015) Current diagnosis and treatment of basal cell carcinoma. Jddg: J Dtsch Dermatologischen Ges 13(9):863\u2013875. https:\/\/doi.org\/10.1111\/ddg.12798","journal-title":"Jddg: J Dtsch Dermatologischen Ges"},{"issue":"3","key":"2273_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00347-016-0370-1","volume":"114","author":"V Kakkassery","year":"2017","unstructured":"Kakkassery\u00a0V, Loeffler\u00a0KU, Sand\u00a0M et\u00a0al (2017) Aktuelle Diagnostik und Therapieempfehlungen beim Basalzellkarzinom am Auge. Ophthalmologe 114(3):224\u2013236. https:\/\/doi.org\/10.1007\/s00347-016-0370-1","journal-title":"Ophthalmologe"},{"key":"2273_CR4","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OTT.S130371","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi\u00a0Y, Jia\u00a0R, Fan\u00a0X (2017) Ocular basal cell carcinoma: A\u00a0brief literature review of clinical diagnosis and treatment. Onco Targets Ther 10:2483\u20132489. https:\/\/doi.org\/10.2147\/OTT.S130371","journal-title":"Onco Targets Ther"},{"key":"2273_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113254","author":"K Peris","year":"2023","unstructured":"Peris\u00a0K, Fargnoli\u00a0MC, Kaufmann\u00a0R et\u00a0al (2023) European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma\u2014update 2023. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2023.113254","journal-title":"Eur J Cancer"},{"key":"2273_CR6","volume-title":"S2k-Leitlinie Basalzellkarzinom Der Haut","author":"BM Lang","year":"2023","unstructured":"Lang\u00a0BM, Balermpas\u00a0P, Bauer\u00a0A et\u00a0al (2023) S2k-Leitlinie 032-021 \u201cBasalzellkarzinom\u201d. In: S2k-Leitlinie Basalzellkarzinom Der Haut"},{"key":"2273_CR7","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OTT.S130371","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi\u00a0Y, Jia\u00a0R, Fan\u00a0X (2017) Ocular basal cell carcinoma: A\u00a0brief literature review of clinical diagnosis and treatment. Onco Targets Ther 10:2483\u20132489. https:\/\/doi.org\/10.2147\/OTT.S130371","journal-title":"Onco Targets Ther"},{"key":"2273_CR8","volume-title":"BAP1 Tumor Predisposition Syndrome","author":"R Pilarski","year":"1993","unstructured":"Pilarski\u00a0R, Byrne\u00a0L, Carlo\u00a0MI, Hanson\u00a0H, Cebulla\u00a0C, Abdel-Rahman\u00a0M (1993) BAP1 Tumor Predisposition Syndrome"},{"issue":"3","key":"2273_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/cge.12472","volume":"88","author":"A de la Fouchardi\u00e8re","year":"2015","unstructured":"de la Fouchardi\u00e8re\u00a0A, Cabaret\u00a0O, Savin\u00a0L et\u00a0al (2015) Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet 88(3):273\u2013277. https:\/\/doi.org\/10.1111\/cge.12472","journal-title":"Clin Genet"},{"issue":"6","key":"2273_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1309\/AJCPG8LFJC0DHDQT","volume":"143","author":"MC Mochel","year":"2015","unstructured":"Mochel\u00a0MC, Piris\u00a0A, Nose\u00a0V, Hoang\u00a0MP (2015) Loss of BAP1 expression in basal cell carcinomas in patients with germline BAP1 mutations. Am J Clin Pathol 143(6):901\u2013904. https:\/\/doi.org\/10.1309\/AJCPG8LFJC0DHDQT","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/cge.12501","volume":"88","author":"KAW Wadt","year":"2015","unstructured":"Wadt\u00a0KAW, Aoude\u00a0LG, Johansson\u00a0P et\u00a0al (2015) A\u00a0recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 88(3):267\u2013272. https:\/\/doi.org\/10.1111\/cge.12501","journal-title":"Clin Genet"},{"issue":"2","key":"2273_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ophtha.2017.07.018","volume":"125","author":"E Szalai","year":"2018","unstructured":"Szalai\u00a0E, Wells\u00a0JR, Ward\u00a0L, Grossniklaus\u00a0HE (2018) Uveal Melanoma Nuclear BRCA\u00a01-Associated Protein\u20111 Immunoreactivity Is an Indicator of Metastasis. Ophthalmology 125(2):203\u2013209. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.018","journal-title":"Ophthalmology"},{"issue":"8","key":"2273_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","volume":"133","author":"MP Gupta","year":"2015","unstructured":"Gupta\u00a0MP, Lane\u00a0AM, DeAngelis\u00a0MM et\u00a0al (2015) Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol 133(8):881\u2013887. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.1119","journal-title":"JAMA Ophthalmol"},{"key":"2273_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.ophtha.2016.01.008","volume":"123","author":"JA Turunen","year":"2016","unstructured":"Turunen\u00a0JA, Markkinen\u00a0S, Wilska\u00a0R et\u00a0al (2016) BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma. Ophthalmology 123:1112\u20131117. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.008","journal-title":"Ophthalmology"},{"issue":"2","key":"2273_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/pcmr.12046","volume":"26","author":"LG Aoude","year":"2013","unstructured":"Aoude\u00a0LG, Vajdic\u00a0CM, Kricker\u00a0A, Armstrong\u00a0B, Hayward\u00a0NK (2013) Prevalence of germline BAP1 mutation in a\u00a0population-based sample of uveal melanoma cases. pigment Cell Melanoma Res 26(2):278\u2013279. https:\/\/doi.org\/10.1111\/pcmr.12046","journal-title":"pigment Cell Melanoma Res"},{"issue":"3","key":"2273_CR16","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele\u00a0W, Stegner\u00a0HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138\u2013140","journal-title":"Pathologe"},{"key":"2273_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2023.101906","author":"RZ Lin","year":"2023","unstructured":"Lin\u00a0RZ, Hong\u00a0AR, Harocopos\u00a0GJ (2023) Primary bulbar conjunctival basal cell carcinoma: A\u00a0clinical-pathologic report and literature review. am J Ophthalmol Case Rep. https:\/\/doi.org\/10.1016\/j.ajoc.2023.101906","journal-title":"am J Ophthalmol Case Rep"},{"issue":"9","key":"2273_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/02713683.2018.1478980","volume":"43","author":"U Kaiser","year":"2018","unstructured":"Kaiser\u00a0U, Loeffler\u00a0KU, Nadal\u00a0J, Holz\u00a0FG, Herwig-Carl\u00a0MC (2018) Polarization and Distribution of Tumor-Associated Macrophages and COX\u20112 Expression in Basal Cell Carcinoma of the Ocular Adnexae. Curr Eye Res 43(9):1126\u20131135. https:\/\/doi.org\/10.1080\/02713683.2018.1478980","journal-title":"Curr Eye Res"},{"issue":"7","key":"2273_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/ceo.12298","volume":"42","author":"A Wu","year":"2014","unstructured":"Wu\u00a0A, Sun\u00a0MT, Huilgol\u00a0SC, Madge\u00a0S, Selva\u00a0D (2014) Histological subtypes of periocular basal cell carcinoma. Clin Exp Ophthalmol 42(7):603\u2013607. https:\/\/doi.org\/10.1111\/ceo.12298","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"2273_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/gcc.22724","volume":"58","author":"C Melzer","year":"2019","unstructured":"Melzer\u00a0C, Sharma\u00a0A, Peters\u00a0S et\u00a0al (2019) Basal cell carcinomas developing independently from BAP1-tumor predisposition syndrome in a\u00a0patient with bilateral uveal melanoma: Diagnostic challenges to identify patients with BAP1-TPDS. Genes Chromosomes Cancer 58(6):357\u2013364. https:\/\/doi.org\/10.1002\/gcc.22724","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"2273_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000486370","volume":"4","author":"M Herwig-Carl","year":"2018","unstructured":"Herwig-Carl\u00a0M, Sharma\u00a0A, Moulin\u00a0A, Strack\u00a0C, Loeffler\u00a0KU (2018) BAP1 Immunostaining in Uveal Melanoma: Potentials and Pitfalls. Ocul Oncol Pathol 4(5):297. https:\/\/doi.org\/10.1159\/000486370","journal-title":"Ocul Oncol Pathol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02273-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-025-02273-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02273-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:50:10Z","timestamp":1756299010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-025-02273-z"}},"subtitle":["Eine retrospektive Analyse an einer Universit\u00e4ts-Augenklinik","A retrospective analysis at a university eye clinic"],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s00347-025-02273-z","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Meinke, K.U.\u00a0L\u00f6ffler, Y.N.\u00a0Liermann, F.G.\u00a0Holz und M.C.\u00a0Herwig-Carl geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}